- Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
- Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre Therapeutics Announces $180 Million Private Placement
More ▼
Key statistics
On Friday, Spyre Therapeutics Inc (SYRE:NSQ) closed at 34.95, -27.14% below its 52-week high of 47.97, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.45 |
---|---|
High | 35.83 |
Low | 34.13 |
Bid | 14.02 |
Offer | 39.00 |
Previous close | 34.05 |
Average volume | 303.42k |
---|---|
Shares outstanding | 50.78m |
Free float | 35.73m |
P/E (TTM) | -- |
Market cap | 1.77bn USD |
EPS (TTM) | -71.35 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼